When you're concerned about an economic downturn, a relatively safe solution is to stick with famous names like Merck (NYSE: MRK ). I recommend holding MRK stock, reinvesting the dividend payments ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research on the company's oncology portfolio addressing ...

Merck (MRK) closed at $104.01 in the latest trading session, marking a +0.41% move from the prior day.

Merck & Co confirmed that its cancer drug Keytruda has successfully met the second of its two primary targets in a phase III clinical trial,  showing significant improvement as a treatment administ...

Merck & Co. said Tuesday a late-stage trial of its blockbuster cancer drug Keytruda as a treatment for several types of non-small cell lung cancer, or NSCLC, met its primary endpoint of overall sur...

The latest trading day saw Merck (MRK) settling at $103.88, representing a +0.27% change from its previous close.

Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.

In the most recent trading session, Merck (MRK) closed at $103.60, indicating a +1.4% shift from the previous trading day.

Merck & Co Inc (NYSE:MRK) has announced promising results from its phase III clinical trial of its blockbuster cancer drug Keytruda in people with certain types of bladder cancer. The study met one...

Merck & Co. Inc. MRK, +0.39% said Thursday a late-stage trial of its cancer treatment Keytruda met its main goal of disease-free survival for patients with advanced bladder cancer. The Rahway, N.J.

The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.

Shares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Resear...

There is still no evidence that molnupiravir, sold under the brand name Lagevrio, has produced more transmissible or severe variants of Covid.

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.